Oppenheimer Releases a Buy Rating on Taysha Gene Therapies (TSHA)

Oppenheimer analyst Kevin DeGeeter assigned a Buy rating to Taysha Gene Therapies (TSHAResearch Report) yesterday and set a price target of $42.00. The company’s shares closed last Wednesday at $27.91, close to its 52-week high of $29.76.

According to TipRanks.com, DeGeeter is a top 100 analyst with an average return of 57.6% and a 62.2% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, Rocket Pharmaceuticals, and Ionis Pharmaceuticals.

Currently, the analyst consensus on Taysha Gene Therapies is a Strong Buy with an average price target of $36.20.

See today’s analyst top recommended stocks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.